The University of Pennsylvania’s pioneering cell therapy physician Carl June shared new data Monday that showed the risk of secondary cancers following CAR-T therapy was very low.
In over 1,500 patients treated at UPenn and Stanford University, only a small percentage had a second cancer after treatment, June reported Monday morning at a Friends of Cancer Research and Parker Institute for Cancer Immunotherapy joint event in Washington.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.